Chronic myeloid leukemia (CML) is characterized by the formation of the BCR-ABL fusion gene. The BCR-ABL protein leads to an increased level of reactive oxygen species, which is a major cause of endogenous DNA double-strand breaks (DSBs). CML cells are prone to rely on a highly mutagenic alternative end-joining (Alt-EJ) pathway to cope with enhanced DSBs, which aggravates chromosomal instability. Hence, targeting dysregulated DNA repair proteins provides new insights into cancer treatment. In this study, we discovered the abnormal upregulation of Flap endonuclease 1 (FEN1) in CML, as well as FEN1's participation in the error-prone Alt-EJ repair pathway and its interplay with DNA Ligase1 and proliferating cell nuclear antigen in DSB repair. Knockdown of FEN1 by shRNA not only inhibited the proliferation and induced apoptosis but also enhanced the efficacy of imatinib (IM) in drug-resistant CML cell K562/G01. Moreover, excessive DSB accumulation was detected after FEN1 inhibition. In summary, our results demonstrated that FEN1 is a promising therapeutic target in CML treatment. This work extends the understanding of regulating abnormal DSB repair for cancer treatment.
Get full access to this article
View all access options for this article.
References
1.
BalakrishnanL., and BambaraR. (2013). Flap endonuclease 1. Ann Rev Biochem, 82, 119–138.
2.
BradyN., GaymesT., CheungM., MuftiG., and RassoolF. (2003). Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins. Cancer Res, 63, 1798–1805.
3.
BryantH., SchultzN., ThomasH., ParkerK., FlowerD., LopezE., et al. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434, 913–917.
4.
ChangH., PannunzioN., AdachiN., and LieberM. (2017). Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol, 18, 495–506.
5.
ChenU., ChenS., SahaP., and DuttaA. (1996). p21Cip1/Waf1 disrupts the recruitment of human Fen1 by proliferating-cell nuclear antigen into the DNA replication complex. Proc Natl Acad Sci U S A, 93, 11597–11602.
6.
ChengQ., BarbouleN., FritP., GomezD., BombardeO., CoudercB., et al. (2011). Ku counteracts mobilization of PARP1 and MRN in chromatin damaged with DNA double-strand breaks. Nuclic Acids Res, 39, 9605–9619.
7.
ChristmannM., TomicicM., RoosW., and KainaB. (2003). Mechanisms of human DNA repair: an update. Toxicology, 193, 3–34.
8.
DrukerB. (2008). Translation of the Philadelphia chromosome into therapy for CML. Blood, 112, 4808–4817.
9.
DrukerB., GuilhotF., O'BrienS., GathmannI., KantarjianH., GattermannN., et al. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355, 2408–2417.
10.
FanJ., LiL., SmallD., and RassoolF. (2010). Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy. Blood, 116, 5298–5305.
11.
FarmerH., McCabeN., LordC., TuttA., JohnsonD., RichardsonT., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434, 917–921.
12.
FernandesM., ReddyM., GonnevilleJ., DeRooS., PodarK., GriffinJ., et al. (2009). BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood, 114, 1813–1819.
13.
GaymesT., MuftiG., and RassoolF. (2002). Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. Cancer Res, 62, 2791–2797.
14.
GostissaM., AltF., and ChiarleR. (2011). Mechanisms that promote and suppress chromosomal translocations in lymphocytes. Ann Rev Immunol, 29, 319–350.
15.
GöttlichB., ReichenbergerS., FeldmannE., and PfeifferP. (1998). Rejoining of DNA double-strand breaks in vitro by single-strand annealing. Eur J Biochem, 258, 387–395.
16.
HanahanD., and WeinbergR. (2011). Hallmarks of cancer: the next generation. Cell, 144, 646–674.
17.
HoleP., DarleyR., and TonksA. (2011). Do reactive oxygen species play a role in myeloid leukemias?. Blood, 117, 5816–5826.
18.
Iacobuzio-DonahueC., MaitraA., OlsenM., LoweA., van HeekN., RostyC., et al. (2003). Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol, 162, 1151–1162.
19.
KlunglandA., and LindahlT. (1997). Second pathway for completion of human DNA base excision-repair: reconstitution with purified proteins and requirement for DNase IV (FEN1). EMBO J, 16, 3341–3348.
20.
KrauseA., CombaretV., IaconoI., LacroixB., CompagnonC., BergeronC., et al. (2005). Genome-wide analysis of gene expression in neuroblastomas detected by mass screening. Cancer Lett, 225, 111–120.
21.
KrejciL., AltmannovaV., SpirekM., and ZhaoX. (2012). Homologous recombination and its regulation. Nucleic Acids Res, 40, 5795–5818.
22.
LamJ., SeligsonD., YuH., LiA., EevaM., PantuckA., et al. (2006). Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score. BJU Int, 98, 445–451.
23.
LiX., LiJ., HarringtonJ., LieberM., and BurgersP. (1995). Lagging strand DNA synthesis at the eukaryotic replication fork involves binding and stimulation of FEN-1 by proliferating cell nuclear antigen. J Biol Chem, 270, 22109–22112.
24.
LiangX., SunH., ShenW., and CrookeS. (2015). Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Res, 43, 2927–2945.
25.
LieberM. (1997). The FEN-1 family of structure-specific nucleases in eukaryotic DNA replication, recombination and repair. Bioessays, 19, 233–240.
26.
LiuY., KaoH., BambaraR. (2004). Flap endonuclease 1: a central component of DNA metabolism. Ann Rev Biochem, 73, 589–615.
27.
LugoT., PendergastA., MullerA., and WitteO. (1990). Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (New York, NY), 247, 1079–1082.
28.
MaL., CaoX., WangH., LuK., WangY., TuC., et al. (2019). Discovery of myricetin as a potent inhibitor of human flap endonuclease 1, which potentially can be used as sensitizing agent against HT-29 human colon cancer cells. J Agricult Food Chem, 67, 1656–1665.
29.
MengwasserK., AdeyemiR., LengY., ChoiM., ClairmontC., D'AndreaA., et al. (2019). Genetic screens reveal FEN1 and APEX2 as BRCA2 synthetic lethal targets. Mol Cell, 73, 885–899.e6.
30.
MuvarakN., NagariaP., and RassoolF. (2012). Genomic instability in chronic myeloid leukemia: targets for therapy?. Curr Hematol Malign Rep, 7, 94–102.
31.
NikolovaT., ChristmannM., and KainaB. (2009). FEN1 is overexpressed in testis, lung and brain tumors. Anticancer Res, 29, 2453–2459.
32.
NowickiM., FalinskiR., KoptyraM., SlupianekA., StoklosaT., GlocE., et al. (2004). BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood, 104, 3746–3753.
33.
RenR. (2005). Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer, 5, 172–183.
34.
SallmyrA., FanJ., and RassoolF. (2008a) Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett, 270, 1–9.
35.
SallmyrA., TomkinsonA., and RassoolF. (2008b) Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks. Blood, 112, 1413–1423.
36.
SinghP., YangM., DaiH., YuD., HuangQ., TanW., et al. (2008). Overexpression and hypomethylation of flap endonuclease 1 gene in breast and other cancers. Mol Cancer Res, 6, 1710–1717.
37.
SkorskiT. (2002). BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene, 21, 8591–8604.
38.
TianK., BakkerE., HussainM., GuazzelliA., AlhebshiH., MeysamiP., et al. (2018). p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification. J Transl Med 16,282.
39.
TobinL., RobertC., NagariaP., ChumsriS., TwaddellW., IoffeO., et al. (2012). Targeting abnormal DNA repair in therapy-resistant breast cancers. Mol Cancer Res, 10, 96–107.
40.
TobinL., RobertC., RapoportA., GojoI., BaerM., TomkinsonA., et al. (2013). Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias. Oncogene, 32, 1784–1793.
41.
WangK., XieC., and ChenD. (2014). Flap endonuclease 1 is a promising candidate biomarker in gastric cancer and is involved in cell proliferation and apoptosis. Int J Mol Med, 33, 1268–1274.
42.
WatersC., StrandeN., WyattD., PryorJ., and RamsdenD. (2014). Nonhomologous end joining: a good solution for bad ends. DNA Repair, 17, 39–51.
43.
YuanY., BrittonS., DelteilC., CoatesJ., JacksonS.P., BarbouleN., et al. (2015). Single-stranded DNA oligomers stimulate error-prone alternative repair of DNA double-strand breaks through hijacking Ku protein. Nucleic Acids Res, 43, 10264–10276.
44.
ZhengL., DaiH., QiuJ., HuangQ., and ShenB. (2007). Disruption of the FEN-1/PCNA interaction results in DNA replication defects, pulmonary hypoplasia, pancytopenia, and newborn lethality in mice. Mol Cell Biol, 27, 3176–3186.
45.
ZhuH., LiuT., MengW., and JiaY. (2007). [Establishment of an imatinib resistance cell line K562R and its resistant principia]. J Sichuan Univ Med Sci, 38, 22–26.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
